314 related articles for article (PubMed ID: 17497463)
1. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
2. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
4. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
5. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
Hood SA; O'Brien M; Higgins R
Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
9. Use of iron sucrose in dialysis patients sensitive to iron dextran.
Haddad A; Abbadi R; Marji A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):208-11. PubMed ID: 19237805
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia.
Reddy CM; Kathula SK; Ali SA; Bekal R; Walsh M
Int J Clin Pract; 2008 Mar; 62(3):413-5. PubMed ID: 18005041
[TBL] [Abstract][Full Text] [Related]
11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
12. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron therapy: well-tolerated, yet not harmless.
Sengölge G; Hörl WH; Sunder-Plassmann G
Eur J Clin Invest; 2005 Dec; 35 Suppl 3():46-51. PubMed ID: 16281958
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
[TBL] [Abstract][Full Text] [Related]
17. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
18. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
19. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.
Macdougall IC; Roche A
Am J Kidney Dis; 2005 Aug; 46(2):283-9. PubMed ID: 16112047
[TBL] [Abstract][Full Text] [Related]
20. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
